KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Income (2016 - 2025)

Historic Net Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$163.1 million.

  • CRISPR Therapeutics AG's Net Income fell 10646.97% to -$163.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$614.1 million, marking a year-over-year decrease of 5052.6%. This contributed to the annual value of -$614.1 million for FY2025, which is 5053.29% down from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Net Income stood at -$163.1 million, which was down 10646.97% from -$106.4 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Net Income ranged from a high of $759.2 million in Q2 2021 and a low of -$208.6 million during Q2 2025
  • Over the past 5 years, CRISPR Therapeutics AG's median Net Income value was -$114.9 million (recorded in 2021), while the average stood at -$74.1 million.
  • Its Net Income has fluctuated over the past 5 years, first soared by 105287.85% in 2021, then tumbled by 23481.09% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Net Income stood at -$141.2 million in 2021, then rose by 20.1% to -$112.9 million in 2022, then skyrocketed by 151.93% to $58.6 million in 2023, then tumbled by 234.81% to -$79.0 million in 2024, then tumbled by 106.47% to -$163.1 million in 2025.
  • Its Net Income was -$163.1 million in Q4 2025, compared to -$106.4 million in Q3 2025 and -$208.6 million in Q2 2025.